Prescribing Empiric Antibiotics for Febrile Neutropenia: Compliance with Institutional Febrile Neutropenia Guidelines

被引:10
|
作者
Naeem, Doaa [1 ]
Alshamrani, Majed A. [1 ]
Aseeri, Mohammed A. [1 ]
Khan, Mansoor A. [1 ]
机构
[1] King Saud Bin Abdul Aziz Univ Hlth Sci, Pharmaceut Care Dept, Minist Natl Guard Hlth Affairs, King Abdul Aziz Med City, King, WI, Saudi Arabia
来源
PHARMACY | 2018年 / 6卷 / 03期
关键词
empiric; antibiotics; febrile; neutropenia; compliance;
D O I
10.3390/pharmacy6030083
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Febrile neutropenia (FN) is an oncologic emergency which should be treated immediately with empiric antibiotics. Different institutions observe different antibiograms and use different FN management guidelines. Our center implemented FN management guidelines for adult cancer patients in 2009. Hence, we decided to assess compliance with FN management guidelines and to describe the pattern of bacterial infections. Method: We conducted a cross-sectional study on all adult cancer patients admitted with FN. Data were collected from electronic medical records between January and December 2014. Results: One hundred FN episodes met the study inclusion criteria. The mean age of the patients was 41 +/- 17 years; 52% (52 patients) were women. The most common diagnosis was lymphoma (33%). In terms of compliance to institutional FN guidelines, 55% of patients received guideline non-compliant treatment. The most common non-compliant treatment was incorrect amikacin dosing in 31% of patients, followed by incorrect vancomycin dosing in 20%, incorrect piperacillin/tazobactam dosing in 19%, inappropriate use of carbapenems in 18%, and non-compliant vancomycin use in 12% of patients. Bacterial isolates were only observed in 19% of the FN episodes. Among these 19 episodes of FN, Gram-negative pathogens were predominant and were identified in 74% of the episodes, followed by Gram-positive pathogens in 16% and polymicrobial pathogens in 10%. The mean time to defervescence was 2.21 +/- 2 days. Conclusion: Our study concluded that there was a high percentage of non-compliance with our institutional FN management guidelines. We recommend following appropriate empiric antibiotic doses and indications as per institutional guidelines.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] COMPLIANCE WITH FEBRILE NEUTROPENIA MANAGEMENT AN EXPERIENCE FROM QATAR
    Yassin, M.
    El-Ayoubi, H.
    Kamzoul, R.
    El-Ghazouani, H.
    HAEMATOLOGICA, 2012, 97 : 569 - 569
  • [32] Withholding antibiotics from patients with febrile neutropenia - Reply
    De Bont, ESJM
    Nijhuis, CO
    Gietema, JA
    Van der Graaf, WTA
    Daenen, SMGJ
    Vellenga, E
    TenVergert, EM
    Vermeulen, KM
    Groen, HJM
    Kamps, WA
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (07) : 1222 - 1223
  • [33] Time to antibiotics and outcomes in cancer patients with febrile neutropenia
    Thomas Perron
    Mohamed Emara
    Shahid Ahmed
    BMC Health Services Research, 14
  • [34] Epidemiology of Febrile Neutropenia
    Doger de Speville, B. G.
    Huelves Garcia, M.
    Lopez Gonzalez, A.
    Ibeas Millan, P. J.
    Perez Callejo, D.
    Almagro Casado, E.
    Maximiano Alonso, C.
    Mendez Garcia, M.
    Cantos Sanchez de Ibargueen, B.
    Provencio Pulla, M.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S249 - S250
  • [35] What is febrile neutropenia?
    不详
    ARCHIVES OF DISEASE IN CHILDHOOD, 2020, 105 (08) : 729 - 729
  • [36] The prevention of febrile neutropenia
    Pascoe, Jennifer
    Cullen, Michael
    CURRENT OPINION IN ONCOLOGY, 2006, 18 (04) : 325 - 329
  • [37] Management of febrile neutropenia
    Rolfes, N.
    Luemmen, G.
    UROLOGE, 2011, 50 (07): : 810 - 812
  • [38] Febrile neutropenia in children
    Kebudi, Rejin
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2007, 29 : S11 - S12
  • [39] FEBRILE NEUTROPENIA IN PEDIATRIC ONCOLOGY: A REGIONAL QUALITY IMPROVEMENT STUDY OF GUIDELINES FOR FEBRILE NEUTROPENIA UPTAKE AND TARGETED KNOWLEDGE TRANSLATION
    Price, V.
    Bernstein, M.
    MacDonald, T.
    Digout, C.
    Johnson, C.
    PEDIATRIC BLOOD & CANCER, 2015, 62 : S389 - S389
  • [40] Carbapenems and febrile neutropenia
    Alfandari, S.
    Berthon, C.
    Ader, F.
    CLINICAL MICROBIOLOGY AND INFECTION, 2017, 23 (03) : 212 - 213